𝗗𝗿. 𝗗𝗿𝗮𝗴𝘂𝗹𝗮’𝘀 𝗖𝗼𝗺𝗽𝗮𝗿𝗮𝘁𝗶𝘃𝗲 𝗦𝘁𝘂𝗱𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 𝗶𝗩𝗔𝗖𝟮𝗟 𝗽𝗩𝗔𝗗 𝗦𝘂𝗽𝗽𝗼𝗿𝘁 𝗶𝗻 𝗛𝗶𝗴𝗵-𝗥𝗶𝘀𝗸 𝗣𝗖𝗜; “𝖢𝗈𝗆𝗉𝖺𝗋𝖺𝗍𝗂𝗏𝖾 𝖮𝗎𝗍𝖼𝗈𝗆𝖾𝗌 𝗈𝖿 𝗂𝖵𝖠𝖢𝟤𝖫 𝖺𝗇𝖽 𝖨𝖠𝖡𝖯 𝖲𝗎𝗉𝗉𝗈𝗋𝗍 𝗂𝗇 𝖧𝗂𝗀𝗁-𝖱𝗂𝗌𝗄 𝖯𝖢𝖨: 𝖲𝗂𝗑-𝖬𝗈𝗇𝗍𝗁 𝖲𝗎𝗋𝗏𝗂𝗏𝖺𝗅 𝖺𝗇𝖽 𝖢𝗈𝗆𝗉𝗅𝗂𝖼𝖺𝗍𝗂𝗈𝗇 𝖠𝗇𝖺𝗅𝗒𝗌𝗂𝗌” 𝗂𝗇 𝗍𝗁𝖾…

…

PulseCath is proud sponsor at the upcoming EUMS-Conference in Hannover on 11 – 14 September 2024. The congress is going to become a Joint-EUMS-Mayo-Hannover-Heart-Conference. This partnership will facilitate…

We are grateful to announce Dr. Grzegorz Sobieszek, Head of the Department of Cardiology, as official proctor for PulseCath iVAC 2L – pVAD – Percutaneous Ventricular Assist Device,…

⚡️PulseCath expands in Asia-Pacific (APAC) region.⚡️In Hong Kong the first successful Complex High Risk and Indicated (CHIP) PCI case with the support of iVAC 2L, pulsatile percutaneous ventricular assist…

📢 Last week PulseCath closed a great EuroPCR again. As every year, great interest, many fruitful meetings, discussions and contacts. Some highligths: 🚩E-poster – Pulsatile mechanical circulatory support…

Excited to share some highlights from EuroPCR 2024 in Paris! Join us for sessions featuring iVAC 2L technology, pulsatile percutaneous ventricular assist device, for protected Complex Higher-risk Indicated…

We are thrilled to announce the first TEACH Course in the Center of Excellence for PulseCath iVAC 2L, pVAD – Percutaneous Ventricular Assist Device, in Italy hosted by…

🌟 The CEO Views is proud to recognize PulseCath, a medical device company as one of the ‘Top 50 Most Innovative Companies to Watch 2024’. The award felicitates…

🚀 We are thrilled to announce the first protected High-Risk PCI with the successful support of iVAC 2L performed by Drs. Hatim Al-Lawati and Dr. Khalid Al-Saidi Royal…